ATE440095T1 - Benzimidazolderivate und ihre verwendung als aii rezeptor-antagonist - Google Patents

Benzimidazolderivate und ihre verwendung als aii rezeptor-antagonist

Info

Publication number: ATE440095T1
Authority: AT; Austria
Prior art keywords: receptor antagonists; benzimidazole derivatives; aii receptor; aii; benzimidazole
Prior art date: 2004-02-25

Application number

AT07075609T

Other languages

English (en)

Inventor

Takanobu Kuroita

Hiroki Sakamoto

Mami Ojima

Original Assignee

Takeda Pharmaceutical

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-02-25

Filing date

2005-02-23

Publication date

2009-09-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34858222&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE440095(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-02-23 Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical

2009-09-15 Application granted granted Critical

2009-09-15 Publication of ATE440095T1 publication Critical patent/ATE440095T1/de

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Hematology (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Pyrrole Compounds (AREA)

AT07075609T 2004-02-25 2005-02-23 Benzimidazolderivate und ihre verwendung als aii rezeptor-antagonist ATE440095T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2004048928		2004-02-25
US11/031,057 US7157584B2 (en)	2004-02-25	2005-01-07	Benzimidazole derivative and use thereof

Publications (1)

Publication Number	Publication Date
ATE440095T1 true ATE440095T1 (de)	2009-09-15

Family

ID=34858222

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT07075609T ATE440095T1 (de)	2004-02-25	2005-02-23	Benzimidazolderivate und ihre verwendung als aii rezeptor-antagonist
AT05719737T ATE370136T1 (de)	2004-02-25	2005-02-23	Benzimidazolderivate und ihre verwendung als antagonisten des a ii rezeptors

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AT05719737T ATE370136T1 (de)	2004-02-25	2005-02-23	Benzimidazolderivate und ihre verwendung als antagonisten des a ii rezeptors

Country Status (34)

Country	Link
US (3)	US7157584B2 (de)
EP (3)	EP1857457B1 (de)
JP (2)	JP4256852B2 (de)
KR (1)	KR101080029B1 (de)
CN (2)	CN100503605C (de)
AR (2)	AR047972A1 (de)
AT (2)	ATE440095T1 (de)
AU (1)	AU2005214271B8 (de)
BE (1)	BE2012C025I2 (de)
BR (2)	BR122012009489B8 (de)
CA (1)	CA2557538C (de)
CY (5)	CY1107008T1 (de)
DE (3)	DE602005002030T2 (de)
DK (3)	DK1718641T3 (de)
ES (3)	ES2331209T3 (de)
HK (2)	HK1098472A1 (de)
HR (3)	HRP20070510T3 (de)
HU (1)	HUS1200008I1 (de)
IL (1)	IL177533A (de)
LU (1)	LU91962I2 (de)
MA (1)	MA28478B1 (de)
ME (2)	ME01089B (de)
MY (1)	MY142807A (de)
NL (1)	NL300802I2 (de)
NO (2)	NO332344B1 (de)
NZ (1)	NZ549755A (de)
PL (3)	PL2119715T3 (de)
PT (3)	PT1718641E (de)
RS (3)	RS52376B (de)
RU (2)	RU2369608C2 (de)
SI (3)	SI1718641T1 (de)
TW (1)	TWI336702B (de)
WO (1)	WO2005080384A2 (de)
ZA (1)	ZA200607241B (de)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7157584B2 (en) *	2004-02-25	2007-01-02	Takeda Pharmaceutical Company Limited	Benzimidazole derivative and use thereof
ES2425567T3 (es)	2004-12-24	2013-10-16	Spinifex Pharmaceuticals Pty Ltd	Método de tratamiento o profilaxis
JP4465469B2 (ja) *	2005-02-21	2010-05-19	国立大学法人佐賀大学	循環器病マーカーとしてのインターロイキン１３
GEP20115138B (en) *	2005-03-30	2011-01-10	Takeda Pharmaceuticals Co	Benzimidazole derivative and use as angiotensin ii antagonist
WO2007097452A1 (ja) *	2006-02-27	2007-08-30	Takeda Pharmaceutical Company Limited	医薬用ブリスターパッケージ
EP1990052B1 (de) *	2006-02-27	2012-05-16	Takeda Pharmaceutical Company Limited	Pharmazeutische packung enthaltend (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl-2-ethoxy-1-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-1h-benzimidazol-7-carboxylat oder (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl-2-cyclopropyl-1-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-1h-benzimidazol-7-carboxylat und ein trockenmittel
AU2007229322B2 (en) *	2006-03-20	2012-04-05	Novartis Ag	Method of treatment or prophylaxis inflammatory pain
ATE552818T1 (de) *	2006-09-25	2012-04-15	Takeda Pharmaceutical	Medizinische verpackung
NZ579851A (en) *	2007-03-28	2012-02-24	Takeda Pharmaceutical	Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a ph control agent
JP2009062296A (ja) *	2007-09-05	2009-03-26	Fujifilm Corp	カルボン酸エステル化合物の製造方法
JP5554699B2 (ja) *	2008-03-13	2014-07-23	第一三共株式会社	オルメサルタンメドキソミルを含む製剤の溶出性の改善
TW201008915A (en) *	2008-07-31	2010-03-01	Takeda Pharmaceutical	Solid pharmaceutical composition
UY32126A (es)	2008-09-25	2010-04-30	Takeda Pharmaceutical	Composición farmacéutica sólida
MX2011004258A (es) *	2008-10-22	2011-06-01	Merck Sharp & Dohme	Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos.
US9387249B2 (en)	2008-12-23	2016-07-12	Takeda Pharmaceutical Company Limited	Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone
US20110009347A1 (en) *	2009-07-08	2011-01-13	Yin Liang	Combination therapy for the treatment of diabetes
EA022365B1 (ru)	2010-05-11	2015-12-30	Янссен Фармацевтика Нв	Фармацевтические композиции, содержащие производные 1-(бета-d-глюкопиранозил)-2-тиенилметилбензола как ингибиторы нзпг
WO2012090043A1 (en)	2010-12-29	2012-07-05	Jubilant Life Sciences Limited	Novel solid state forms of azilsartan medoxomil and preparation thereof
BR112013017982A2 (pt)	2011-01-20	2020-10-27	Jiangsu Hansoh Pharmaceutical Co., Ltd.	sais orgânicos de amina de azilsartan, processo de preparação e uso dos mesmos
CA2840818C (en)	2011-02-08	2018-12-11	Jubilant Life Sciences Limited	An improved process for the preparation of azilsartan medoxomil
CN102138899B (zh) *	2011-03-18	2013-08-21	海南本创医药科技有限公司	阿齐沙坦酯脂质体固体制剂
RS55056B1 (sr)	2011-04-13	2016-12-30	Janssen Pharmaceutica Nv	Proces za pripremu jedinjenja koja su korisna kao inhibitori sglt2
CN102827153B (zh) *	2011-06-14	2016-10-05	江苏豪森药业集团有限公司	阿齐沙坦的晶型及其制备方法
CN102351853B (zh) *	2011-08-29	2014-03-12	石药集团欧意药业有限公司	一种阿齐沙坦酯化合物、制备方法及其药物组合物
WO2013042067A1 (en)	2011-09-20	2013-03-28	Ranbaxy Laboratories Limited	Process for the preparation of potassium salt of azilsartan medoxomil
WO2013042066A1 (en)	2011-09-20	2013-03-28	Ranbaxy Laboratories Limited	Process for the preparation of azilsartan medoxomil
WO2013088384A2 (en)	2011-12-15	2013-06-20	Jubilant Life Sciences Limited	Solid state forms of azilsartan and azilsartan medoxomil monopotassium and preparation thereof
AP2014007766A0 (en)	2011-12-15	2014-07-31	Takeda Pharmaceuticals Usa Inc	Combination os azilsartan and chlorthlidone for treating hypertension black patients
CN104039779B (zh) *	2012-01-14	2016-08-24	广东东阳光药业有限公司	阿齐沙坦酯钾的晶型及其制备方法及其用途
WO2013114305A1 (en) *	2012-02-02	2013-08-08	Ranbaxy Laboratories Limited	Process for the preparation of azilsartan medoxomil or pharmaceutically acceptable salts thereof
WO2013124748A1 (en) *	2012-02-20	2013-08-29	Alembic Pharmaceuticals Limited	Novel polymorphs of azilsartan medoxomil potassium
CZ2012274A3 (cs) *	2012-04-19	2013-10-30	Zentiva, K.S.	Zpusob prípravy vysoce cisté draselné soli azilsartanu medoxomilu
WO2013186792A2 (en) *	2012-06-11	2013-12-19	Msn Laboratories Limited	Process for the preparation of (5-methyl-2-oxo-l,3-dioxoi-4-vl)methvl 2- ethoxv-l-{[2'-(5-oxo-4,5-dihvdro-l,2,4-oxadiazol-3-vl)biphenyi-4-vl]methyl}- lh-benzimidazole-7-carboxyiate and its salts
US20150291574A1 (en) *	2012-07-09	2015-10-15	Bandi Parthasaradhi Reddy	Novel polymorphs of azilsartan
WO2014020381A1 (en) *	2012-08-01	2014-02-06	Alembic Pharmaceuticals Limited	Novel crystalline form of azilsartan medoxomil potassium
WO2014033740A1 (en)	2012-08-27	2014-03-06	Hetero Research Foundation	Novel polymorphs of azilsartan medoxomil
WO2014049512A2 (en)	2012-09-26	2014-04-03	Lupin Limited	Novel process for preparation of azilsartan medoxomil
CZ305318B6 (cs) *	2012-09-26	2015-07-29	Zentiva, K.S.	Způsob přípravy vysoce čisté draselné soli azilsartanu medoxomilu
CN105237527B (zh) *	2012-09-28	2018-03-06	武汉朗来科技发展有限公司	苯并咪唑衍生物及其制备方法和医药用途
IN2015DN03071A (de) *	2012-10-09	2015-10-02	Avery Dennison Corp
CN103910720A (zh) *	2013-01-07	2014-07-09	广东东阳光药业有限公司	阿齐沙坦酯的新晶型及其制备方法
CN105153141B (zh) *	2013-02-04	2018-09-25	武汉朗来科技发展有限公司	苯并咪唑衍生物及其制备方法和医药用途
JP6281735B2 (ja) *	2013-03-19	2018-02-21	トーアエイヨー株式会社	急性心不全治療薬の評価方法、及び、急性心不全モデルの作製方法
RU2535005C1 (ru) *	2013-06-11	2014-12-10	Николай Андреевич Козлов	Способ лечения грыж межпозвонковых дисков у собак
RU2535004C1 (ru) *	2013-06-11	2014-12-10	Николай Андреевич Козлов	Способ лечения грыж межпозвонковых дисков у собак
WO2015051546A1 (zh) *	2013-10-12	2015-04-16	杭州领业医药科技有限公司	阿齐沙坦酯的晶型及其制备方法
CN105949182B (zh) *	2013-10-12	2019-03-19	杭州领业医药科技有限公司	阿齐沙坦酯的晶型及其制备方法
CN104774196B (zh) *	2014-01-09	2017-11-10	武汉朗来科技发展有限公司	一种苯并咪唑衍生物的制备方法
CN104774197B (zh) *	2014-01-09	2017-11-17	武汉朗来科技发展有限公司	一种苯并咪唑衍生物的制备方法
CN105079815A (zh) *	2014-04-30	2015-11-25	广东东阳光药业有限公司	一种阿齐沙坦酯钾组合物及其制备方法
CN104016974A (zh) *	2014-06-24	2014-09-03	浙江天宇药业股份有限公司	阿齐沙坦酯中间体及其合成方法、阿齐沙坦酯的合成方法
CZ2014702A3 (cs)	2014-10-15	2016-04-27	Zentiva, K.S.	Způsob přípravy vysoce čistého azilsartanu
CN105622595A (zh) *	2014-11-21	2016-06-01	重庆朗天制药有限公司	一种阿奇沙坦酯钾盐及其中间体新的制备方法
CN105753854A (zh) *	2014-12-16	2016-07-13	重庆朗天制药有限公司	一种阿齐沙坦酯钾盐的新制备方法
US9708306B2 (en)	2015-03-18	2017-07-18	Wuhan Ll Science And Technology Development Co., Ltd	Benzimidazole derivatives and preparation process and pharmaceutical uses thereof
CN106032378B (zh) *	2015-03-20	2019-10-25	武汉启瑞药业有限公司	新型arb化合物及其用途
CN104803998B (zh) *	2015-03-26	2017-08-25	晋江市托美汀生物科技有限公司	一种降低杂质含量的方法
CA2992796A1 (en) *	2015-07-29	2017-02-02	Takeda Gmbh	Pde4 inhibitor for the treatment of diabetic nephropathy
US20170071970A1 (en)	2015-09-15	2017-03-16	Janssen Pharmaceutica Nv	Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
JP6856365B2 (ja) *	2016-11-30	2021-04-07	株式会社トクヤマ	アジルサルタンの製造方法
CN109071519A (zh) *	2016-01-28	2018-12-21	株式会社德山	阿齐沙坦及其制造方法
CN105628824B (zh) *	2016-03-06	2017-10-17	江苏正大清江制药有限公司	一种高效液相色谱法测定阿齐沙坦原料中有关物质的方法
CN107400122B (zh) *	2016-05-20	2020-10-23	武汉朗来科技发展有限公司	化合物及其制备方法、组合物和应用
CN105770876B (zh) *	2016-05-30	2019-09-10	广东天普生化医药股份有限公司	乌司他丁在制备治疗慢性前列腺炎药物中的用途
RU2623082C1 (ru) *	2016-07-11	2017-06-21	Государственное бюджетное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации	Способ коррекции артериальной ригидности у больных ревматоидным артритом
CN107602546B (zh) *	2016-07-11	2022-04-22	武汉朗来科技发展有限公司	化合物的晶型及其制备方法、组合物和应用
RU2634272C1 (ru) *	2016-08-10	2017-10-24	Закрытое акционерное общество "Санкт-Петербургский институт фармации"	Композиция с дезамино-аргинин-вазотоцином для парентерального введения и способ её получения
CN106074416A (zh) *	2016-08-30	2016-11-09	佛山市弘泰药物研发有限公司	一种阿齐沙坦酯钾盐分散片的制备方法
US11096928B2 (en) *	2016-10-08	2021-08-24	Wuhan Ll Science And Technology Development Co., Ltd.	Pharmaceutical composition
WO2019130277A1 (en)	2017-12-30	2019-07-04	Lupin Limited	Pharmaceutical formulations of azilsartan medoxomil
CN110237071B (zh) *	2018-03-09	2022-03-22	武汉朗来科技发展有限公司	药物制剂及其应用
CN110237072B (zh) *	2018-03-09	2022-03-25	武汉朗来科技发展有限公司	药物组合物的制备方法
CN112567469B (zh) *	2018-06-14	2023-11-07	阿斯利康(英国)有限公司	用血管紧张素ii受体阻滞剂医药组合物治疗高血压的方法
CN112955965B (zh) *	2018-06-14	2024-04-09	阿斯利康(英国)有限公司	使用二氢吡啶类钙通道阻断剂医药组合物降低血压的方法
KR20200057662A (ko)	2018-11-16	2020-05-26	엠에프씨 주식회사	아질사르탄 유도체 화합물, 이의 중간체, 이의 제조방법 및 이를 포함하는 조성물
JP7573272B2 (ja)	2019-02-15	2024-10-25	国立大学法人東北大学	１，３－ジオキソラン誘導体
KR102220011B1 (ko)	2020-05-15	2021-02-25	대봉엘에스 주식회사	친환경 용매를 이용한 아질사탄의 제조방법 및 이에 관한 핵심 중간체 화합물
CN113912580B (zh) *	2021-11-03	2023-06-02	瑞孚信江苏药业股份有限公司	一种纯化4-(羟甲基)-5-甲基-[1,3]二氧杂环戊烯-2-酮的方法
CA3231724A1 (en)	2021-12-28	2023-07-06	Alchemedicine, Inc.	Compound, angiotensin ii type 1 receptor antagonist and pharmaceutical composition
KR20240039252A (ko)	2022-09-19	2024-03-26	대봉엘에스 주식회사	안지오텐신 ⅱ 길항제로서의 아질사르탄 디시클로헥실아민 및 이를 유효성분으로 하는 심혈관질환 치료 또는 예방용 약학적 조성물
CN118059247A (zh) *	2022-11-24	2024-05-24	上海云晟研新生物科技有限公司	包含美阿沙坦钾与钙通道阻滞剂的药物组合物，及其制备方法及应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS62290071A (ja)	1986-06-09	1987-12-16	Matsushita Electric Ind Co Ltd	有機電解質二次電池
US5196444A (en)	1990-04-27	1993-03-23	Takeda Chemical Industries, Ltd.	1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
IE920540A1 (en)	1991-02-21	1992-08-26	Sankyo Co	1-biphenylmethylimidazole derivatives, their preparation and¹their therapetuic use
US5616599A (en)	1991-02-21	1997-04-01	Sankyo Company, Limited	Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
IL102183A (en)	1991-06-27	1999-11-30	Takeda Chemical Industries Ltd	The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them
RU2117668C1 (ru) *	1991-10-23	1998-08-20	Эйсаи Ко., Лтд.	Производное оксазолидона или его фармакологически приемлемые соли, фармацевтическая композиция, способ лечения
US5310929A (en)	1992-08-06	1994-05-10	E. I. Du Pont De Nemours And Company	Prodrugs of imidazole carboxylic acids as angiotensin II receptor antagonists
US5605919A (en) *	1993-02-26	1997-02-25	Takeda Chemical Industries, Ltd.	Treatment for viral diseases
TW403748B (en) *	1994-11-02	2000-09-01	Takeda Chemical Industries Ltd	An oxazolidinedione derivative, its production and a pharmaceutical composition for lowering blood sugar and lipid in blood comprising the same
US5610314A (en)	1995-04-03	1997-03-11	Bristol-Myers Squibb Company	Process for preparing dioxolenone derivatives used for making prodrug esters and intermediates
AU2001269516B2 (en)	2000-07-13	2006-09-14	Takeda Pharmaceutical Company Limited	Lipid-rich plaque regressing agents
WO2003047573A1 (fr)	2001-12-03	2003-06-12	Takeda Chemical Industries, Ltd.	Agents pour améliorer l'état de résistance à l'insuline
CN1615305A (zh)	2002-01-11	2005-05-11	武田药品工业株式会社	香豆素衍生物、生产它们的方法及其用途
EP1564213A4 (de)	2002-11-22	2009-05-27	Takeda Pharmaceutical	Imidazolderivat, verfahren zu dessenherstellung und verwendung
US6972258B2 (en) *	2003-08-04	2005-12-06	Taiwan Semiconductor Manufacturing Co., Ltd.	Method for selectively controlling damascene CD bias
US7157584B2 (en) *	2004-02-25	2007-01-02	Takeda Pharmaceutical Company Limited	Benzimidazole derivative and use thereof
JP4364171B2 (ja)	2005-07-15	2009-11-11	本田技研工業株式会社	自動車用ドアチェッカ
UA58542U (ru) *	2010-12-16	2011-04-11	Леонид Борисович Борейко	Способ фиксирования эвакуационной машины во время вытягивания застрявшей тяжелой машины

2005
- 2005-01-07 US US11/031,057 patent/US7157584B2/en active Active
- 2005-02-23 DE DE602005002030T patent/DE602005002030T2/de active Active
- 2005-02-23 AT AT07075609T patent/ATE440095T1/de active
- 2005-02-23 ES ES07075609T patent/ES2331209T3/es active Active
- 2005-02-23 ME MEP-2009-323A patent/ME01089B/me unknown
- 2005-02-23 EP EP07075609A patent/EP1857457B1/de active Active
- 2005-02-23 BR BR122012009489A patent/BR122012009489B8/pt active IP Right Grant
- 2005-02-23 WO PCT/JP2005/003422 patent/WO2005080384A2/en active Application Filing
- 2005-02-23 PL PL08075903T patent/PL2119715T3/pl unknown
- 2005-02-23 MY MYPI20050690A patent/MY142807A/en unknown
- 2005-02-23 RS RS20120362A patent/RS52376B/en unknown
- 2005-02-23 KR KR1020067016710A patent/KR101080029B1/ko active Protection Beyond IP Right Term
- 2005-02-23 SI SI200530072T patent/SI1718641T1/sl unknown
- 2005-02-23 PT PT05719737T patent/PT1718641E/pt unknown
- 2005-02-23 CA CA2557538A patent/CA2557538C/en active Active
- 2005-02-23 RU RU2006133898/04A patent/RU2369608C2/ru active Protection Beyond IP Right Term
- 2005-02-23 TW TW094105364A patent/TWI336702B/zh active
- 2005-02-23 RU RU2009115498/04A patent/RU2501798C2/ru active Protection Beyond IP Right Term
- 2005-02-23 AU AU2005214271A patent/AU2005214271B8/en active Active
- 2005-02-23 DK DK05719737T patent/DK1718641T3/da active
- 2005-02-23 EP EP05719737A patent/EP1718641B1/de active Active
- 2005-02-23 CN CNB2005800130733A patent/CN100503605C/zh active Active
- 2005-02-23 SI SI200531568T patent/SI2119715T1/sl unknown
- 2005-02-23 RS RSP-2007/0448A patent/RS50537B/sr unknown
- 2005-02-23 PL PL05719737T patent/PL1718641T3/pl unknown
- 2005-02-23 ME MEP-2007-448A patent/ME01643B/me unknown
- 2005-02-23 CN CN2008101701465A patent/CN101381366B/zh active Active
- 2005-02-23 JP JP2005047294A patent/JP4256852B2/ja active Active
- 2005-02-23 DE DE602005016162T patent/DE602005016162D1/de active Active
- 2005-02-23 ES ES08075903T patent/ES2388945T3/es active Active
- 2005-02-23 PL PL07075609T patent/PL1857457T3/pl unknown
- 2005-02-23 DK DK07075609T patent/DK1857457T3/da active
- 2005-02-23 ES ES05719737T patent/ES2293552T3/es active Active
- 2005-02-23 EP EP08075903A patent/EP2119715B1/de active Active
- 2005-02-23 AT AT05719737T patent/ATE370136T1/de active
- 2005-02-23 NZ NZ549755A patent/NZ549755A/en unknown
- 2005-02-23 PT PT08075903T patent/PT2119715E/pt unknown
- 2005-02-23 PT PT07075609T patent/PT1857457E/pt unknown
- 2005-02-23 AR ARP050100653A patent/AR047972A1/es active IP Right Grant
- 2005-02-23 DK DK08075903.8T patent/DK2119715T3/da active
- 2005-02-23 BR BRPI0507984A patent/BRPI0507984B8/pt active IP Right Grant
- 2005-02-23 RS RSP-2009/0484A patent/RS51137B/sr unknown
- 2005-02-23 SI SI200530822T patent/SI1857457T1/sl unknown
2006
- 2006-08-16 IL IL177533A patent/IL177533A/en active IP Right Grant
- 2006-08-23 US US11/466,633 patent/US7572920B2/en active Active
- 2006-08-30 ZA ZA2006/07241A patent/ZA200607241B/en unknown
- 2006-09-20 NO NO20064251A patent/NO332344B1/no active Protection Beyond IP Right Term
- 2006-09-22 MA MA29333A patent/MA28478B1/fr unknown
2007
- 2007-05-04 HK HK07104818A patent/HK1098472A1/xx unknown
- 2007-11-05 HR HR20070510T patent/HRP20070510T3/xx unknown
- 2007-11-14 CY CY20071101476T patent/CY1107008T1/el unknown
2008
- 2008-04-29 HK HK08104744.3A patent/HK1115118A1/xx unknown
- 2008-12-22 JP JP2008325152A patent/JP2009137974A/ja active Pending
2009
- 2009-06-30 US US12/458,092 patent/US7875637B2/en active Active
- 2009-11-04 HR HR20090593T patent/HRP20090593T1/hr unknown
- 2009-11-12 CY CY20091101184T patent/CY1109610T1/el unknown
2012
- 2012-03-21 LU LU91962C patent/LU91962I2/fr unknown
- 2012-03-29 DE DE201212000018 patent/DE122012000018I1/de active Pending
- 2012-05-17 HU HUS1200008C patent/HUS1200008I1/hu unknown
- 2012-05-31 CY CY2012015C patent/CY2012015I2/el unknown
- 2012-05-31 CY CY2012016C patent/CY2012016I1/el unknown
- 2012-06-07 BE BE2012C025C patent/BE2012C025I2/fr unknown
- 2012-08-17 HR HRP20120667TT patent/HRP20120667T2/hr unknown
- 2012-08-29 CY CY20121100774T patent/CY1113084T1/el unknown
- 2012-11-09 NO NO2012017C patent/NO2012017I1/no not_active IP Right Cessation
2014
- 2014-01-27 AR ARP140100236A patent/AR094588A2/es not_active Application Discontinuation
2016
- 2016-03-15 NL NL300802C patent/NL300802I2/nl unknown

Also Published As

Publication number	Publication date
DE602005002030T2 (de)	2008-05-08
DK2119715T3 (da)	2012-09-10
EP2119715A1 (de)	2009-11-18
HK1098472A1 (en)	2007-07-20
ES2331209T3 (es)	2009-12-23
AR047972A1 (es)	2006-03-15
CA2557538C (en)	2010-08-17
NO332344B1 (no)	2012-09-03
DE602005002030D1 (de)	2007-09-27
ATE370136T1 (de)	2007-09-15
HUS1200008I1 (hu)	2017-06-28
DK1857457T3 (da)	2009-12-21
SI2119715T1 (sl)	2012-10-30
RU2369608C2 (ru)	2009-10-10
NO2012017I2 (no)	2012-11-09
DE602005016162D1 (de)	2009-10-01
DE122012000018I1 (de)	2012-06-06
EP1857457A3 (de)	2007-12-05
US20060281795A1 (en)	2006-12-14
RS50537B (sr)	2010-05-07
AR094588A2 (es)	2015-08-12
NL300802I2 (de)	2016-05-18
EP2119715B1 (de)	2012-05-30
ES2388945T3 (es)	2012-10-22
HRP20120667T2 (hr)	2012-11-30
RU2006133898A (ru)	2008-03-27
KR20070020411A (ko)	2007-02-21
CY1113084T1 (el)	2016-04-13
CY1107008T1 (el)	2012-09-26
BRPI0507984B1 (pt)	2018-07-03
BRPI0507984B8 (pt)	2023-03-21
AU2005214271A2 (en)	2005-09-01
ZA200607241B (en)	2008-04-30
TW200530227A (en)	2005-09-16
CY2012016I2 (el)	2016-12-14
SI1718641T1 (sl)	2007-12-31
DK1718641T3 (da)	2007-12-17
US7157584B2 (en)	2007-01-02
CY2012015I1 (el)	2016-12-14
WO2005080384A3 (en)	2006-09-28
MA28478B1 (fr)	2007-03-01
CY2012016I1 (el)	2016-12-14
AU2005214271B8 (en)	2011-03-03
PT1857457E (pt)	2009-09-23
CN101381366A (zh)	2009-03-11
EP1718641B1 (de)	2007-08-15
JP2009137974A (ja)	2009-06-25
IL177533A (en)	2010-12-30
US7875637B2 (en)	2011-01-25
MY142807A (en)	2011-01-14
HRP20120667T1 (en)	2012-09-30
HRP20090593T1 (hr)	2010-03-31
RS51137B (sr)	2010-10-31
TWI336702B (en)	2011-02-01
US20050187269A1 (en)	2005-08-25
BE2012C025I2 (de)	2024-08-08
AU2005214271B2 (en)	2011-02-24
CN100503605C (zh)	2009-06-24
BRPI0507984A (pt)	2007-07-24
JP4256852B2 (ja)	2009-04-22
HRP20070510T3 (en)	2007-12-31
PL1718641T3 (pl)	2008-01-31
HK1115118A1 (en)	2008-11-21
JP2005272451A (ja)	2005-10-06
AU2005214271A1 (en)	2005-09-01
SI1857457T1 (sl)	2010-01-29
RU2501798C2 (ru)	2013-12-20
EP1857457A2 (de)	2007-11-21
BR122012009489B8 (pt)	2023-03-21
NZ549755A (en)	2009-04-30
US20090270464A1 (en)	2009-10-29
PL1857457T3 (pl)	2009-12-31
BR122012009489B1 (pt)	2019-02-19
PT1718641E (pt)	2007-11-15
EP1857457B1 (de)	2009-08-19
NO2012017I1 (no)	2012-11-26
ME01089B (me)	2013-03-20
PL2119715T3 (pl)	2012-10-31
CY2012015I2 (el)	2016-12-14
ES2293552T3 (es)	2008-03-16
LU91962I2 (fr)	2012-05-21
US7572920B2 (en)	2009-08-11
ME01643B (me)	2010-05-07
NO20064251L (no)	2006-11-22
CN101381366B (zh)	2011-06-15
WO2005080384A9 (en)	2006-11-30
EP1718641A2 (de)	2006-11-08
PT2119715E (pt)	2012-09-03
RU2009115498A (ru)	2010-10-27
IL177533A0 (en)	2006-12-10
CA2557538A1 (en)	2005-09-01
WO2005080384A2 (en)	2005-09-01
CY1109610T1 (el)	2014-08-13
KR101080029B1 (ko)	2011-11-04
RS52376B (en)	2012-12-31
CN1946717A (zh)	2007-04-11

Publication	Publication Date	Title
ATE440095T1 (de)	2009-09-15	Benzimidazolderivate und ihre verwendung als aii rezeptor-antagonist
ATE538130T1 (de)	2012-01-15	Pyrimidinderivate und ihre verwendung als p2y12- rezeptorantagonisten
DE602005023639D1 (de)	2010-10-28	Chinuclidinderivate und deren verwendung als muscarin-m3-rezeptor-antagonisten
ATE473214T1 (de)	2010-07-15	2-(4-oxo-4h-chinazolin-3-yl)acetamide und ihre verwendung als vasopressin-v3-antagonisten
DK1951660T3 (da)	2014-01-27	Histamin-3-receptorantagonister
ATE378338T1 (de)	2007-11-15	Pyrrolopyridinderivate und deren verwendung als crth2-antagonisten
ATE394391T1 (de)	2008-05-15	Indolderivate als histaminrezeptorantagonisten
ATE409182T1 (de)	2008-10-15	Tetrahydrochinolinone und deren verwendung als antagonisten von metabotropen glutamatrezeptoren
ATE454377T1 (de)	2010-01-15	2-phenyl-6-aminocarbonylpyrimidinderivate und ihre verwendung als antagonisten am p2y12- rezeptor
DE602004022458D1 (de)	2009-09-17	Pyrazolderivate und ihre verwendung als orexin-rezeptor-antagonisten
ATE445399T1 (de)	2009-10-15	Pyridyl-derivate und ihre verwendung als mglu5- rezeptorantagonisten
DE60106607D1 (de)	2004-11-25	Substituierte 1-aminoalkyl-lactame und ihre verwendung als muscarinrezeptor antagonisten
ATE382034T1 (de)	2008-01-15	Hydroisoindolin-tachykininrezeptorantagonisten
ATE518834T1 (de)	2011-08-15	2,3,4,9-tetrahydro-1h-carbazol-derivative als crth2-rezeptorantagonisten
ATE471938T1 (de)	2010-07-15	Substituierte diazaspiroä4.5üdecanderivate und deren verwendung als neurokininantagonisten
ATE414078T1 (de)	2008-11-15	Indol-3-ylcarbonylpiperidinbenzimidazolderivate als v1a-rezeptorantagonisten
DE60316411D1 (de)	2007-10-31	Thiazolderivate als npy-rezeptorantagonisten
ATE513817T1 (de)	2011-07-15	Pyrimidinderivate und ihre verwendung als pestizide
ATE377008T1 (de)	2007-11-15	Imidazolderivate als glutamatrezeptorantagonisten
ATE427748T1 (de)	2009-04-15	Pyridin-derivate und ihre verwendung als urotensin ii antagonisten
DE602005009355D1 (de)	2008-10-09	Gehinderte himbacinanaloga als thrombinrezeptorantagonisten
DE602007010179D1 (de)	2010-12-09	Piperidinylaminopyridazine und ihre verwendung als schnelldissoziierende antagonisten des dopamin-2-rezeptors
ATE396185T1 (de)	2008-06-15	Substituierte 4-alkyl- und 4- alkanoylpiperidinderivate und deren verwendung als neurokininantagonisten
DE60317632D1 (de)	2008-01-03	2-oxazolamine und ihre verwendung als 5-ht2b-rezeptor-antagonisten
ATE509012T1 (de)	2011-05-15	Arylindenopyrimidine und ihre verwendung als adenosin-a2a-rezeptorantagonisten

Legal Events

Date	Code	Title	Description
2010-03-15	UEP	Publication of translation of european patent specification	Ref document number: 1857457 Country of ref document: EP

Date

Code

Title

Description

2010-03-15

UEP

Publication of translation of european patent specification

Ref document number: 1857457

Country of ref document: EP